HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Nagano, J. Articles by Kohrogi, H. Search for Related Content PubMed PubMed Citation Articles by Nagano, J. Articles by Kohrogi, H.

Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis

¹ Dept of Respiratory Medicine, Faculty of Medical and Pharmaceutical Sciences, and ² First Dept of Internal Medicine, Kumamoto University, Kumamoto, Japan.

CORRESPONDENCE: H. Kohrogi, Dept of Respiratory Medicine, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Fax: 81 963735012. E-mail: kohrogi{at}kaiju.medic.kumamoto-u.ac.jp

Keywords: Bleomycin, fibroblast, FK506, pulmonary fibrosis, tacrolimus, transforming growth factor-ß

Received: June 16, 2005
Accepted October 25, 2005

Idiopathic pulmonary fibrosis has a poor prognosis and few efficacious treatments. The immunosuppressant cyclosporin A has been shown to inhibit tumour growth factor (TGF)-ß-induced collagen deposition in vitro, and is widely used in Japan as a potent antifibrotic agent. Tacrolimus (FK506) is another attractive immunosuppressant, which may be useful in the treatment of pulmonary fibrosis. The aim of the present study was to elucidate the antifibrotic effect of FK506.

The inhibitory effect of FK506 on collagen synthesis in cultured lung fibroblastic cells, TIG-3-20, and its antifibrotic effect on bleomycin (BLM)-induced pulmonary fibrosis in mice was investigated.

FK506 inhibited TGF-ß-induced collagen synthesis, and suppressed the expression of TGF-ß type I receptor (TßR-I) in TIG-3-20 cells. Consistent with the in vitro findings, FK506 treatment starting on day 6 attenuated BLM-induced pulmonary fibrosis, in part, via reduced TßR-I expression. FK506 treatment in the acute BLM injury phase unexpectedly increased pro-inflammatory cytokine levels in bronchoalveolar lavage fluid and enhanced lung injury, resulting in poor survival.

In conclusion, the present results suggest that FK506 has a potent antifibrotic effect and may be useful for the treatment of pulmonary fibrosis, although its use in the acute inflammatory phase may exacerbate lung injury.